| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 5 | 2020 | 713 | 0.840 |
Why?
|
| Tumor Suppressor Protein p53 | 10 | 2020 | 3552 | 0.800 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2019 | 47 | 0.800 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2016 | 5437 | 0.730 |
Why?
|
| Keratosis | 1 | 2019 | 39 | 0.720 |
Why?
|
| Alopecia | 1 | 2019 | 126 | 0.680 |
Why?
|
| Keratins | 5 | 2004 | 330 | 0.610 |
Why?
|
| Head and Neck Neoplasms | 10 | 2023 | 3976 | 0.600 |
Why?
|
| Genes, ras | 4 | 2011 | 667 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 476 | 0.490 |
Why?
|
| Salivary Gland Neoplasms | 6 | 2015 | 489 | 0.480 |
Why?
|
| Mutation | 12 | 2020 | 15179 | 0.420 |
Why?
|
| Precancerous Conditions | 2 | 2017 | 1058 | 0.420 |
Why?
|
| Stress, Physiological | 1 | 2014 | 492 | 0.400 |
Why?
|
| Genes, p53 | 3 | 2015 | 1090 | 0.390 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.380 |
Why?
|
| Gene Deletion | 2 | 2016 | 1442 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2016 | 8873 | 0.350 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 5112 | 0.310 |
Why?
|
| Disease Models, Animal | 10 | 2023 | 7222 | 0.280 |
Why?
|
| Aging | 1 | 2014 | 1582 | 0.280 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2015 | 421 | 0.270 |
Why?
|
| Keratinocytes | 4 | 2009 | 241 | 0.270 |
Why?
|
| Animals | 26 | 2024 | 59536 | 0.260 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2024 | 11 | 0.240 |
Why?
|
| Mice | 21 | 2024 | 34495 | 0.240 |
Why?
|
| Apoptosis | 6 | 2017 | 7591 | 0.240 |
Why?
|
| Skin Neoplasms | 7 | 2014 | 4654 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2015 | 755 | 0.230 |
Why?
|
| NFI Transcription Factors | 2 | 2015 | 74 | 0.220 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 1866 | 0.210 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2022 | 107 | 0.200 |
Why?
|
| 4-Nitroquinoline-1-oxide | 2 | 2017 | 41 | 0.190 |
Why?
|
| Papilloma | 3 | 2011 | 74 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 2359 | 0.180 |
Why?
|
| Adrenergic Neurons | 1 | 2020 | 11 | 0.180 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2023 | 259 | 0.180 |
Why?
|
| Hair Follicle | 1 | 2019 | 64 | 0.180 |
Why?
|
| Quinolones | 2 | 2017 | 160 | 0.170 |
Why?
|
| Intermediate Filaments | 2 | 2006 | 27 | 0.170 |
Why?
|
| Carcinogens | 2 | 2017 | 384 | 0.170 |
Why?
|
| Cell Transdifferentiation | 1 | 2020 | 112 | 0.170 |
Why?
|
| Epidermis | 1 | 2019 | 188 | 0.170 |
Why?
|
| Epithelial Cells | 3 | 2004 | 1818 | 0.170 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 141 | 0.160 |
Why?
|
| Disease Progression | 5 | 2020 | 6682 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 1130 | 0.160 |
Why?
|
| Hyperplasia | 1 | 2019 | 557 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 1823 | 0.160 |
Why?
|
| Translocation, Genetic | 2 | 2015 | 1245 | 0.160 |
Why?
|
| Caspases | 2 | 2015 | 661 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 189 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 5 | 2023 | 6942 | 0.150 |
Why?
|
| Granzymes | 1 | 2017 | 91 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 5159 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 1756 | 0.150 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 156 | 0.150 |
Why?
|
| Cysteine Endopeptidases | 1 | 1997 | 251 | 0.140 |
Why?
|
| Carcinoma, Ductal | 2 | 2014 | 145 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 2045 | 0.140 |
Why?
|
| Oncogenes | 2 | 2013 | 673 | 0.140 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 216 | 0.130 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 119 | 0.130 |
Why?
|
| Ligands | 1 | 2017 | 995 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 4143 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2015 | 290 | 0.120 |
Why?
|
| Salivary Ducts | 1 | 2014 | 56 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 1538 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 275 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 1021 | 0.120 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 3343 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2017 | 1144 | 0.110 |
Why?
|
| Mesoderm | 1 | 1995 | 404 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 278 | 0.110 |
Why?
|
| Databases, Genetic | 1 | 2016 | 745 | 0.110 |
Why?
|
| Mitosis | 2 | 2014 | 615 | 0.110 |
Why?
|
| Humans | 28 | 2024 | 261506 | 0.110 |
Why?
|
| Cell Line, Tumor | 8 | 2016 | 14551 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 1033 | 0.110 |
Why?
|
| Models, Animal | 1 | 2014 | 664 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2020 | 5270 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2015 | 1555 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 234 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 413 | 0.100 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 171 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2019 | 4078 | 0.100 |
Why?
|
| Cisplatin | 2 | 2015 | 2432 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2011 | 179 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 1070 | 0.090 |
Why?
|
| Oncogene Fusion | 1 | 2010 | 63 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1586 | 0.090 |
Why?
|
| Genes, myc | 1 | 2011 | 358 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 589 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2020 | 2947 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2011 | 246 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 5395 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 4757 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 4367 | 0.080 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 878 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2014 | 1764 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 992 | 0.080 |
Why?
|
| Mice, Nude | 5 | 2014 | 4307 | 0.080 |
Why?
|
| DNA Damage | 2 | 2014 | 1954 | 0.070 |
Why?
|
| Keratin-10 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Centrosome | 1 | 2007 | 95 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7548 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 2864 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3869 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 980 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2488 | 0.070 |
Why?
|
| Feedback, Physiological | 2 | 2020 | 193 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 3639 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2007 | 369 | 0.070 |
Why?
|
| Glycine | 1 | 2007 | 289 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.060 |
Why?
|
| Female | 9 | 2020 | 141928 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2006 | 5710 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 10035 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2014 | 11965 | 0.060 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2004 | 47 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 239 | 0.060 |
Why?
|
| Epithelium | 2 | 1997 | 720 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5178 | 0.060 |
Why?
|
| Arginine | 1 | 2007 | 500 | 0.060 |
Why?
|
| Cell Line, Transformed | 2 | 1995 | 394 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2020 | 3101 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2024 | 166 | 0.060 |
Why?
|
| Male | 10 | 2020 | 123000 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2011 | 3536 | 0.060 |
Why?
|
| Pyrimidinones | 2 | 2015 | 314 | 0.060 |
Why?
|
| ras Proteins | 1 | 2007 | 770 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2015 | 1053 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 1062 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 2086 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2015 | 1313 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2009 | 108 | 0.050 |
Why?
|
| Cetuximab | 1 | 2023 | 472 | 0.050 |
Why?
|
| Carcinoma | 1 | 1993 | 2578 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 4549 | 0.050 |
Why?
|
| Alleles | 1 | 2007 | 2437 | 0.050 |
Why?
|
| Protein Binding | 2 | 2014 | 3438 | 0.050 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 1082 | 0.050 |
Why?
|
| Concanavalin A | 1 | 2000 | 67 | 0.050 |
Why?
|
| Aurora Kinases | 2 | 2011 | 189 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2020 | 19 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2015 | 7226 | 0.050 |
Why?
|
| Receptors, Adrenergic | 1 | 2020 | 46 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1519 | 0.050 |
Why?
|
| Neurites | 1 | 2020 | 63 | 0.040 |
Why?
|
| Genomics | 3 | 2015 | 2738 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2021 | 241 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1997 | 6089 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 184 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 106 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 242 | 0.040 |
Why?
|
| Aurora Kinase A | 2 | 2011 | 202 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 11538 | 0.040 |
Why?
|
| Gene Expression | 3 | 2014 | 3570 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3821 | 0.040 |
Why?
|
| Cell Movement | 3 | 2014 | 2466 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 470 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 1987 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 301 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2020 | 518 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1021 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2000 | 193 | 0.040 |
Why?
|
| Caspase 6 | 1 | 1997 | 15 | 0.040 |
Why?
|
| Caspase 7 | 1 | 1997 | 35 | 0.040 |
Why?
|
| Enzyme Precursors | 1 | 1997 | 66 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 4844 | 0.040 |
Why?
|
| Peptide Mapping | 1 | 1997 | 114 | 0.040 |
Why?
|
| Genomic Instability | 2 | 2011 | 519 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 612 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 639 | 0.040 |
Why?
|
| Transfection | 2 | 2000 | 2944 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 7789 | 0.040 |
Why?
|
| DNA Copy Number Variations | 2 | 2014 | 1516 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2016 | 78 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13658 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 3981 | 0.040 |
Why?
|
| Caspase 3 | 1 | 1997 | 471 | 0.040 |
Why?
|
| Neoplasms | 1 | 2022 | 15193 | 0.040 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Pyrazoles | 2 | 2015 | 1471 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 2291 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 483 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 104 | 0.030 |
Why?
|
| Gene Order | 1 | 2015 | 111 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 997 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2011 | 2450 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2022 | 1682 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 2489 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2015 | 76 | 0.030 |
Why?
|
| Phenotype | 3 | 2014 | 6295 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 2314 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 289 | 0.030 |
Why?
|
| Injections | 1 | 1995 | 285 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cell Line | 2 | 2000 | 5114 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 317 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2014 | 176 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 54 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 1997 | 1487 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 4314 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2021 | 1154 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 222 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 528 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2000 | 1549 | 0.030 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2013 | 71 | 0.030 |
Why?
|
| Cadherins | 1 | 1996 | 660 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 382 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2013 | 92 | 0.030 |
Why?
|
| Pyrimidines | 2 | 2015 | 3518 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 734 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1077 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2013 | 129 | 0.030 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2013 | 137 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 3154 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 829 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2014 | 584 | 0.020 |
Why?
|
| Salivary Glands | 1 | 2011 | 130 | 0.020 |
Why?
|
| Proteolysis | 1 | 2013 | 370 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 691 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2011 | 331 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2024 | 3341 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1084 | 0.020 |
Why?
|
| Liver | 1 | 2000 | 2961 | 0.020 |
Why?
|
| Gene Fusion | 1 | 2011 | 209 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 6100 | 0.020 |
Why?
|
| Integrins | 1 | 2011 | 262 | 0.020 |
Why?
|
| Base Sequence | 1 | 1996 | 4917 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1995 | 1819 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 987 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1944 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2009 | 93 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1471 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1331 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 842 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1997 | 1341 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2216 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1299 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 1555 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 1869 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2006 | 24 | 0.020 |
Why?
|
| Prognosis | 2 | 2015 | 21713 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 671 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2084 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 4804 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 1203 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1859 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 448 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 815 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 973 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Middle Aged | 4 | 2014 | 86204 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6150 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6207 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2232 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 2265 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 575 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 29902 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 769 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 538 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 598 | 0.010 |
Why?
|
| Biomarkers | 1 | 1995 | 5047 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 14289 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 2171 | 0.010 |
Why?
|
| Adult | 3 | 2014 | 77950 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 15862 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 5673 | 0.010 |
Why?
|
| Aged | 2 | 2014 | 70117 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 37905 | 0.010 |
Why?
|
| Harvey murine sarcoma virus | 1 | 1996 | 1 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 1996 | 81 | 0.010 |
Why?
|
| Chemotaxis | 1 | 1996 | 138 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 568 | 0.010 |
Why?
|
| Methionine | 1 | 1996 | 159 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 682 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 869 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 21445 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1996 | 2927 | 0.010 |
Why?
|